EVIDENCE LIBRARY
When Newborn THC Urine Screens Meet Specimen Contamination
A published study found assay-dependent baby-wash interference in newborn cannabinoid urine screening, making collection and confirmation records essential.
A positive cannabinoid immunoassay is a screening response. It is not, by itself, chemical identification of THC exposure. That distinction becomes especially important when a newborn urine specimen may have contacted cleansing products or collection materials before it reached the analyzer.
A published 2012 study by Cotten and colleagues investigated unexpected cannabinoid-screen results in a newborn nursery. The researchers reported that some tested baby wash products and surfactants produced positive bias in a specific urine cannabinoid immunoassay. They also found that the response depended on the assay. The paper therefore supports a focused conclusion: the entire collection and testing process must be reconstructed before an unconfirmed newborn screen is treated as evidence of cannabis exposure.
A presumptive response is not compound identification
Urine drug-screening immunoassays use antibodies to produce a response associated with a drug class or target metabolite. Their speed makes them useful for screening. Their antibody reactions also make them vulnerable to cross-reactivity and other interference.
A result above the assay cutoff means the screening system produced a response meeting its decision rule. It does not establish that a confirmatory method identified the target compound. It does not determine dose, timing, impairment, or how any detected substance entered the specimen.
That is why a screening result and a confirmed result should remain visibly distinct throughout the laboratory record. For the broader distinction, see Presumptive Urine Drug Screens: Why Confirmation Matters.
Discordant newborn results triggered the investigation
The Cotten investigation began after nursery personnel observed positive newborn urine cannabinoid screens that did not align with corresponding meconium findings. The laboratory and clinical teams reviewed drug histories, specimen differences, and collection practices. Their review identified nursery-specific opportunities for preanalytical variability.
The paper described inconsistent practices involving cleansing, rinsing, urine bags, gauze, cotton, and diapers. A collection device could be applied before or after washing, and the rinsing technique was not standardized. Those details were not peripheral. They defined possible routes by which material on the skin or collection surface could enter a small-volume urine specimen.
Discordant urine and meconium results do not automatically prove contamination. The specimens reflect different biological and analytical conditions. But the discordance gave the laboratory a reason to investigate the workflow instead of assuming that every positive screen represented the intended cannabinoid metabolite.
What the wash-product experiments showed
The investigators added selected nursery products and materials to drug-free urine and tested the mixtures using the laboratory's cannabinoid immunoassay. In the reported Vitros 5600 system, addition of one tested baby wash produced a measurable response. Increasing experimental additions produced a dose-related increase, including responses above the assay's screening threshold under some tested conditions.
Several other tested wash products also produced positive bias. When the researchers tested selected ingredients, some surfactants reacted while sodium lauryl sulfate did not react under the reported conditions. The exact mechanism remained unresolved.
The experiment did not measure the amount of wash present in each questioned clinical specimen. It did not establish that every wash product interferes. It showed that plausible collection-related products could produce an unexpected response in the studied analytical system and that the possibility required investigation.
Assay dependence changes the meaning of an interferent
One of the paper's most important findings was that the observed behavior was reagent dependent. The investigators reported similar dose-related interference with a tested Siemens EMIT assay but not with the tested Beckman Olympus cannabinoid assay.
That difference defeats blanket statements. A product should not be called a universal THC-test interferent merely because it affected one or two tested systems. The relevant questions concern the exact analyzer, reagent formulation, lot, cutoff, matrix, preparation, and conditions used in the questioned analysis.
Package inserts and published cross-reactivity lists are starting points. A laboratory's own interference investigations, complaints, amended reports, and method-verification records may be more probative of what its system did at the relevant time. See Analytical Interferences for the general framework.
Collection practices are part of the analytical record
The paper's initial experiments did not find cannabinoid reactivity from the tested wipes, gauze, cotton balls, diapers, or urine collection bags themselves. That does not make collection documentation irrelevant. Those materials affect how a small urine volume is obtained, transferred, absorbed, recovered, and potentially exposed to material on the skin.
A defensible review should identify who collected the specimen, when cleansing occurred, which product was used, whether rinsing occurred, which collection device or absorbent material was used, how urine was transferred, and whether the submitted volume was sufficient for both screening and confirmation.
The phrase “laboratory error” is often too narrow. The total testing process begins before the specimen enters the laboratory and continues through reporting, communication, and any decision made from the result.
Confirmation can fail when specimen volume is not preserved
After the investigation, the institution described in the paper began reflexing positive newborn urine screens for confirmation. The follow-up exposed another practical problem: some specimens did not contain enough volume to perform confirmation.
That is an evidentiary limitation, not a confirmed positive. If the only available specimen was consumed by screening or was insufficient for the more specific method, the record should say so plainly. A reviewer should not silently upgrade a presumptive result because confirmation became impossible.
The confirmation method, cutoff, aliquot requirement, specimen condition, transfer history, result, and reason for any cancellation belong in the file. Urine and meconium results should also remain analytically distinct rather than being treated as interchangeable proof.
Records needed to review a newborn cannabinoid screen
A meaningful review should request:
- specimen type, collection time, volume, collector, and transfer history;
- cleansing product, timing, rinsing procedure, and collection device;
- diaper, gauze, cotton, bag, or other material contacting the specimen;
- screening platform, reagent name and lot, cutoff, raw response, flags, and package insert;
- calibration, controls, maintenance, proficiency, and interference records;
- chromatograms and identification criteria for any confirmatory analysis;
- confirmation order, aliquot volume, cutoff, result, and reason if it was not completed;
- urine and meconium reports, with their different matrices and detection periods preserved;
- laboratory-provider communications, interpretive comments, and amended reports; and
- collection and reflex-confirmation policies in effect on the analysis date.
The target urinary cannabinoid metabolite is analytically different from parent THC and other metabolites. For terminology and biological context, see Cannabis Metabolites.
The defensible conclusion follows the whole process
The Cotten paper does not prove that all newborn cannabinoid screens are unreliable. It does not establish that every positive result arose from soap contamination. It demonstrates that a population-specific collection workflow and an assay-specific interference can create an erroneous cannabinoid screening response.
The defensible conclusion in an individual matter should follow the actual specimen, collection process, reagent system, raw response, confirmation record, and alternative evidence. A screening label cannot substitute for chemical identification, and an unavailable confirmation cannot be rewritten as one that succeeded.
Source
Cotten SW, Duncan DL, Burch EA, Seashore CJ, Hammett-Stabler CA. Unexpected interference of baby wash products with a cannabinoid (THC) immunoassay. Clinical Biochemistry. 2012;45(9):605-609. DOI.